Lipella Pharmaceuticals to present Phase 2a data for LP-310
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy ?
Clinical Trial Announcement: Lipella Pharmaceuticals will present topline data from its Phase 2a trial of LP-310 for Oral Lichen Planus at the 2025 AAOM and European Association of Oral Medicine meeting in Las Vegas.
Treatment Efficacy Results: The 0.50 mg dose showed significant improvements in various measures, including a reduction in Investigator Global Assessment scores and pain levels after four weeks of treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
